APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Parkinson Disease Drug

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Selected research

Market Structure

Global Parkinson Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174022410321 December 2025195 pages

Choose your research edition.

Industry ResearchParkinson Disease Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Parkinson Disease Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Parkinson Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Parkinson Disease Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Parkinson Disease Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.

Report Includes

Read the full market overview

This report provides an overview of the global Parkinson Disease Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Parkinson Disease Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Parkinson Disease Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Parkinson Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Parkinson Disease Drug Segment by Company

Merck

Akorn

GSK

Novartis

Boehringer Ingelheim

Teva Pharmaceutical

Abbvie

Kyowa Hakko Kirin Pharma

Astellas Pharma

Desitin Arzneimittel

Endo Pharmaceuticals

F.Hoffmann-La Roche

H.Lundbeck

Valeant

Apokyn

Orion

Stada Arzneimittel

US WorldMeds

Bausch Health

Parkinson Disease Drug Segment by Type

Sinemet-CR

Trastal

Madopar

COMT Inhibitor

Other

Parkinson Disease Drug Segment by Application

Under 40 Years Old

40-65 Years Old

Above 65 Years Old

Parkinson Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Parkinson Disease Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parkinson Disease Drug industry.

Chapter 3: Detailed analysis of Parkinson Disease Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinson Disease Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Parkinson Disease Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Sinemet-CR Table 3. Key Players of Trastal Table 4. Key Players of Madopar Table 3. Key Players of COMT Inhibitor Table 4. Key Players of Other Table 5. Global Parkinson Disease Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Under 40 Years Old Table 7. Key Players of 40-65 Years Old Table 8. Key Players of Above 65 Years Old Table 9. Global Parkinson Disease Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Parkinson Disease Drug Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Parkinson Disease Drug Market Share by Region (2021-2026) Table 12. Global Parkinson Disease Drug Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Parkinson Disease Drug Market Share by Region (2027-2032) Table 14. Parkinson Disease Drug Industry Trends Table 15. Parkinson Disease Drug Industry Drivers Table 16. Parkinson Disease Drug Industry Opportunities and Challenges Table 17. Parkinson Disease Drug Industry Restraints Table 18. Global Parkinson Disease Drug Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Parkinson Disease Drug Revenue Market Share by Company (2021-2026) Table 20. Global Parkinson Disease Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Parkinson Disease Drug Key Company Head Office and Area Served Table 22. Global Parkinson Disease Drug Company, Product Type & Application Table 23. Global Parkinson Disease Drug Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Parkinson Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Parkinson Disease Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Parkinson Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Parkinson Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Parkinson Disease Drug Revenue Market Share by Type (2021-2026) Table 30. Global Parkinson Disease Drug Revenue Market Share by Type (2027-2032) Table 31. Global Parkinson Disease Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Parkinson Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Parkinson Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Parkinson Disease Drug Revenue Market Share by Application (2021-2026) Table 35. Global Parkinson Disease Drug Revenue Market Share by Application (2027-2032) Table 36. Merck Company Information Table 37. Merck Business Overview Table 38. Merck Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Merck Parkinson Disease Drug Product Portfolio Table 40. Merck Recent Development Table 41. Akorn Company Information Table 42. Akorn Business Overview Table 43. Akorn Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Akorn Parkinson Disease Drug Product Portfolio Table 45. Akorn Recent Development Table 46. GSK Company Information Table 47. GSK Business Overview Table 48. GSK Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. GSK Parkinson Disease Drug Product Portfolio Table 50. GSK Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novartis Parkinson Disease Drug Product Portfolio Table 55. Novartis Recent Development Table 56. Boehringer Ingelheim Company Information Table 57. Boehringer Ingelheim Business Overview Table 58. Boehringer Ingelheim Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Boehringer Ingelheim Parkinson Disease Drug Product Portfolio Table 60. Boehringer Ingelheim Recent Development Table 61. Teva Pharmaceutical Company Information Table 62. Teva Pharmaceutical Business Overview Table 63. Teva Pharmaceutical Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Teva Pharmaceutical Parkinson Disease Drug Product Portfolio Table 65. Teva Pharmaceutical Recent Development Table 66. Abbvie Company Information Table 67. Abbvie Business Overview Table 68. Abbvie Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Abbvie Parkinson Disease Drug Product Portfolio Table 70. Abbvie Recent Development Table 71. Kyowa Hakko Kirin Pharma Company Information Table 72. Kyowa Hakko Kirin Pharma Business Overview Table 73. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio Table 75. Kyowa Hakko Kirin Pharma Recent Development Table 76. Astellas Pharma Company Information Table 77. Astellas Pharma Business Overview Table 78. Astellas Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Astellas Pharma Parkinson Disease Drug Product Portfolio Table 80. Astellas Pharma Recent Development Table 81. Desitin Arzneimittel Company Information Table 82. Desitin Arzneimittel Business Overview Table 83. Desitin Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Desitin Arzneimittel Parkinson Disease Drug Product Portfolio Table 85. Desitin Arzneimittel Recent Development Table 86. Endo Pharmaceuticals Company Information Table 87. Endo Pharmaceuticals Business Overview Table 88. Endo Pharmaceuticals Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio Table 90. Endo Pharmaceuticals Recent Development Table 91. F.Hoffmann-La Roche Company Information Table 92. F.Hoffmann-La Roche Business Overview Table 93. F.Hoffmann-La Roche Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio Table 95. F.Hoffmann-La Roche Recent Development Table 96. H.Lundbeck Company Information Table 97. H.Lundbeck Business Overview Table 98. H.Lundbeck Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. H.Lundbeck Parkinson Disease Drug Product Portfolio Table 100. H.Lundbeck Recent Development Table 101. Valeant Company Information Table 102. Valeant Business Overview Table 103. Valeant Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Valeant Parkinson Disease Drug Product Portfolio Table 105. Valeant Recent Development Table 106. Apokyn Company Information Table 107. Apokyn Business Overview Table 108. Apokyn Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. Apokyn Parkinson Disease Drug Product Portfolio Table 110. Apokyn Recent Development Table 111. Orion Company Information Table 112. Orion Business Overview Table 113. Orion Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. Orion Parkinson Disease Drug Product Portfolio Table 115. Orion Recent Development Table 116. Stada Arzneimittel Company Information Table 117. Stada Arzneimittel Business Overview Table 118. Stada Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. Stada Arzneimittel Parkinson Disease Drug Product Portfolio Table 120. Stada Arzneimittel Recent Development Table 121. US WorldMeds Company Information Table 122. US WorldMeds Business Overview Table 123. US WorldMeds Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. US WorldMeds Parkinson Disease Drug Product Portfolio Table 125. US WorldMeds Recent Development Table 126. Bausch Health Company Information Table 127. Bausch Health Business Overview Table 128. Bausch Health Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 129. Bausch Health Parkinson Disease Drug Product Portfolio Table 130. Bausch Health Recent Development Table 131. North America Parkinson Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 132. North America Parkinson Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 133. North America Parkinson Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 134. North America Parkinson Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 135. North America Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. North America Parkinson Disease Drug Market Size by Country (2021-2026) Table 137. North America Parkinson Disease Drug Market Size by Country (2027-2032) Table 138. Europe Parkinson Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 139. Europe Parkinson Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 140. Europe Parkinson Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 141. Europe Parkinson Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 142. Europe Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Parkinson Disease Drug Market Size by Country (2021-2026) Table 144. Europe Parkinson Disease Drug Market Size by Country (2027-2032) Table 145. China Parkinson Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 146. China Parkinson Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 147. China Parkinson Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 148. China Parkinson Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 149. Asia Parkinson Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 150. Asia Parkinson Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 151. Asia Parkinson Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 152. Asia Parkinson Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 153. Asia Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Asia Parkinson Disease Drug Market Size by Country (2021-2026) Table 155. Asia Parkinson Disease Drug Market Size by Country (2027-2032) Table 156. South America, Middle East & Africa Parkinson Disease Drug Market Size by Type (2021-2026) & (US$ Million) Table 157. South America, Middle East & Africa Parkinson Disease Drug Market Size by Type (2027-2032) & (US$ Million) Table 158. South America, Middle East & Africa Parkinson Disease Drug Market Size by Application (2021-2026) & (US$ Million) Table 159. South America, Middle East & Africa Parkinson Disease Drug Market Size by Application (2027-2032) & (US$ Million) Table 160. South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2021-2026) Table 162. South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Parkinson Disease Drug Product Image Figure 2. Global Parkinson Disease Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Parkinson Disease Drug Market Share by Type: 2025 VS 2032 Figure 4. Sinemet-CR Image Figure 5. Trastal Image Figure 6. Madopar Image Figure 7. COMT Inhibitor Image Figure 8. Other Image Figure 9. Global Parkinson Disease Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Parkinson Disease Drug Market Share by Application: 2025 VS 2032 Figure 11. Under 40 Years Old Image Figure 12. 40-65 Years Old Image Figure 13. Above 65 Years Old Image Figure 14. Global Parkinson Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 16. Global Parkinson Disease Drug Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Parkinson Disease Drug Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Parkinson Disease Drug Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Parkinson Disease Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Parkinson Disease Drug Revenue Market Share by Type (2021-2032) Figure 23. Global Parkinson Disease Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Parkinson Disease Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 26. North America Parkinson Disease Drug Market Share by Type (2021-2032) Figure 27. North America Parkinson Disease Drug Market Share by Application (2021-2032) Figure 28. North America Parkinson Disease Drug Market Share by Country (2021-2032) Figure 29. United States Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 30. Canada Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 32. Europe Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 33. Europe Parkinson Disease Drug Market Share by Type (2021-2032) Figure 34. Europe Parkinson Disease Drug Market Share by Application (2021-2032) Figure 35. Europe Parkinson Disease Drug Market Share by Country (2021-2032) Figure 36. Germany Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 37. France Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 39. Italy Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 40. Russia Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 42. China Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 43. China Parkinson Disease Drug Market Share by Type (2021-2032) Figure 44. China Parkinson Disease Drug Market Share by Application (2021-2032) Figure 45. Asia Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 46. Asia Parkinson Disease Drug Market Share by Type (2021-2032) Figure 47. Asia Parkinson Disease Drug Market Share by Application (2021-2032) Figure 48. Asia Parkinson Disease Drug Market Share by Country (2021-2032) Figure 49. Japan Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 53. India Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 54. Australia Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Parkinson Disease Drug Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Parkinson Disease Drug Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Parkinson Disease Drug Market Share by Country (2021-2032) Figure 59. Brazil Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 64. UAE Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 66. Chile Parkinson Disease Drug Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Sinemet-CR
  • Trastal
  • Madopar
  • COMT Inhibitor
  • Other
Applications
  • Under 40 Years Old
  • 40-65 Years Old
  • Above 65 Years Old
Companies covered
  • Merck
  • Akorn
  • GSK
  • Novartis
  • Boehringer Ingelheim
  • Teva Pharmaceutical
  • Abbvie
  • Kyowa Hakko Kirin Pharma
  • Astellas Pharma
  • Desitin Arzneimittel
  • Endo Pharmaceuticals
  • F.Hoffmann-La Roche
  • H.Lundbeck
  • Valeant
  • Apokyn
  • Orion
  • Stada Arzneimittel
  • US WorldMeds
  • Bausch Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Parkinson Disease Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Sinemet-CR
  5. 1.2.3 Trastal
  6. 1.2.4 Madopar
  7. 1.2.5 COMT Inhibitor
  8. 1.2.6 Other
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Parkinson Disease Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Under 40 Years Old
  12. 1.3.3 40-65 Years Old
  13. 1.3.4 Above 65 Years Old
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Parkinson Disease Drug Growth Trends by Region
  16. 1.5.1 Global Parkinson Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Parkinson Disease Drug Market Size by Region (2021-2026)
  18. 1.5.3 Parkinson Disease Drug Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Parkinson Disease Drug Market Dynamics
  1. 2.1 Parkinson Disease Drug Industry Trends
  2. 2.2 Parkinson Disease Drug Industry Drivers
  3. 2.3 Parkinson Disease Drug Industry Opportunities and Challenges
  4. 2.4 Parkinson Disease Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Parkinson Disease Drug Revenue by Company (2021-2026)
  2. 3.2 Global Parkinson Disease Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Parkinson Disease Drug Key Company Head office and Area Served
  4. 3.4 Global Parkinson Disease Drug Company, Product Type & Application
  5. 3.5 Global Parkinson Disease Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Parkinson Disease Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Parkinson Disease Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Parkinson Disease Drug Tier 1, Tier 2, and Tier 3
4 Parkinson Disease Drug Market by Type
  1. 4.1 Global Parkinson Disease Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Parkinson Disease Drug Market Size by Type (2021-2032)
  3. 4.3 Global Parkinson Disease Drug Market Size Share by Type (2021-2032)
5 Parkinson Disease Drug Market by Application
  1. 5.1 Global Parkinson Disease Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Parkinson Disease Drug Market Size by Application (2021-2032)
  3. 5.3 Global Parkinson Disease Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Merck
  2. 6.1.1 Merck Company Information
  3. 6.1.2 Merck Business Overview
  4. 6.1.3 Merck Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Merck Parkinson Disease Drug Product Portfolio
  6. 6.1.5 Merck Recent Developments
  7. 6.2 Akorn
  8. 6.2.1 Akorn Company Information
  9. 6.2.2 Akorn Business Overview
  10. 6.2.3 Akorn Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Akorn Parkinson Disease Drug Product Portfolio
  12. 6.2.5 Akorn Recent Developments
  13. 6.3 GSK
  14. 6.3.1 GSK Company Information
  15. 6.3.2 GSK Business Overview
  16. 6.3.3 GSK Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 GSK Parkinson Disease Drug Product Portfolio
  18. 6.3.5 GSK Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Novartis Parkinson Disease Drug Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Boehringer Ingelheim
  26. 6.5.1 Boehringer Ingelheim Company Information
  27. 6.5.2 Boehringer Ingelheim Business Overview
  28. 6.5.3 Boehringer Ingelheim Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
  30. 6.5.5 Boehringer Ingelheim Recent Developments
  31. 6.6 Teva Pharmaceutical
  32. 6.6.1 Teva Pharmaceutical Company Information
  33. 6.6.2 Teva Pharmaceutical Business Overview
  34. 6.6.3 Teva Pharmaceutical Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
  36. 6.6.5 Teva Pharmaceutical Recent Developments
  37. 6.7 Abbvie
  38. 6.7.1 Abbvie Company Information
  39. 6.7.2 Abbvie Business Overview
  40. 6.7.3 Abbvie Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Abbvie Parkinson Disease Drug Product Portfolio
  42. 6.7.5 Abbvie Recent Developments
  43. 6.8 Kyowa Hakko Kirin Pharma
  44. 6.8.1 Kyowa Hakko Kirin Pharma Company Information
  45. 6.8.2 Kyowa Hakko Kirin Pharma Business Overview
  46. 6.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
  48. 6.8.5 Kyowa Hakko Kirin Pharma Recent Developments
  49. 6.9 Astellas Pharma
  50. 6.9.1 Astellas Pharma Company Information
  51. 6.9.2 Astellas Pharma Business Overview
  52. 6.9.3 Astellas Pharma Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Astellas Pharma Parkinson Disease Drug Product Portfolio
  54. 6.9.5 Astellas Pharma Recent Developments
  55. 6.10 Desitin Arzneimittel
  56. 6.10.1 Desitin Arzneimittel Company Information
  57. 6.10.2 Desitin Arzneimittel Business Overview
  58. 6.10.3 Desitin Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
  60. 6.10.5 Desitin Arzneimittel Recent Developments
  61. 6.11 Endo Pharmaceuticals
  62. 6.11.1 Endo Pharmaceuticals Company Information
  63. 6.11.2 Endo Pharmaceuticals Business Overview
  64. 6.11.3 Endo Pharmaceuticals Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
  66. 6.11.5 Endo Pharmaceuticals Recent Developments
  67. 6.12 F.Hoffmann-La Roche
  68. 6.12.1 F.Hoffmann-La Roche Company Information
  69. 6.12.2 F.Hoffmann-La Roche Business Overview
  70. 6.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
  72. 6.12.5 F.Hoffmann-La Roche Recent Developments
  73. 6.13 H.Lundbeck
  74. 6.13.1 H.Lundbeck Company Information
  75. 6.13.2 H.Lundbeck Business Overview
  76. 6.13.3 H.Lundbeck Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 H.Lundbeck Parkinson Disease Drug Product Portfolio
  78. 6.13.5 H.Lundbeck Recent Developments
  79. 6.14 Valeant
  80. 6.14.1 Valeant Company Information
  81. 6.14.2 Valeant Business Overview
  82. 6.14.3 Valeant Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Valeant Parkinson Disease Drug Product Portfolio
  84. 6.14.5 Valeant Recent Developments
  85. 6.15 Apokyn
  86. 6.15.1 Apokyn Company Information
  87. 6.15.2 Apokyn Business Overview
  88. 6.15.3 Apokyn Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Apokyn Parkinson Disease Drug Product Portfolio
  90. 6.15.5 Apokyn Recent Developments
  91. 6.16 Orion
  92. 6.16.1 Orion Company Information
  93. 6.16.2 Orion Business Overview
  94. 6.16.3 Orion Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Orion Parkinson Disease Drug Product Portfolio
  96. 6.16.5 Orion Recent Developments
  97. 6.17 Stada Arzneimittel
  98. 6.17.1 Stada Arzneimittel Company Information
  99. 6.17.2 Stada Arzneimittel Business Overview
  100. 6.17.3 Stada Arzneimittel Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Stada Arzneimittel Parkinson Disease Drug Product Portfolio
  102. 6.17.5 Stada Arzneimittel Recent Developments
  103. 6.18 US WorldMeds
  104. 6.18.1 US WorldMeds Company Information
  105. 6.18.2 US WorldMeds Business Overview
  106. 6.18.3 US WorldMeds Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 US WorldMeds Parkinson Disease Drug Product Portfolio
  108. 6.18.5 US WorldMeds Recent Developments
  109. 6.19 Bausch Health
  110. 6.19.1 Bausch Health Company Information
  111. 6.19.2 Bausch Health Business Overview
  112. 6.19.3 Bausch Health Parkinson Disease Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Bausch Health Parkinson Disease Drug Product Portfolio
  114. 6.19.5 Bausch Health Recent Developments
7 North America
  1. 7.1 North America Parkinson Disease Drug Market Size (2021-2032)
  2. 7.2 North America Parkinson Disease Drug Market Size by Type
  3. 7.2.1 North America Parkinson Disease Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Parkinson Disease Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Parkinson Disease Drug Market Share by Type (2021-2032)
  6. 7.3 North America Parkinson Disease Drug Market Size by Application
  7. 7.3.1 North America Parkinson Disease Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Parkinson Disease Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Parkinson Disease Drug Market Share by Application (2021-2032)
  10. 7.4 North America Parkinson Disease Drug Market Size by Country
  11. 7.4.1 North America Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Parkinson Disease Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Parkinson Disease Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Parkinson Disease Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Parkinson Disease Drug Market Size (2021-2032)
  2. 8.2 Europe Parkinson Disease Drug Market Size by Type
  3. 8.2.1 Europe Parkinson Disease Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Parkinson Disease Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Parkinson Disease Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Parkinson Disease Drug Market Size by Application
  7. 8.3.1 Europe Parkinson Disease Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Parkinson Disease Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Parkinson Disease Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Parkinson Disease Drug Market Size by Country
  11. 8.4.1 Europe Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Parkinson Disease Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Parkinson Disease Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Parkinson Disease Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Parkinson Disease Drug Market Size (2021-2032)
  2. 9.2 China Parkinson Disease Drug Market Size by Type
  3. 9.2.1 China Parkinson Disease Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Parkinson Disease Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Parkinson Disease Drug Market Share by Type (2021-2032)
  6. 9.3 China Parkinson Disease Drug Market Size by Application
  7. 9.3.1 China Parkinson Disease Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Parkinson Disease Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Parkinson Disease Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Parkinson Disease Drug Market Size (2021-2032)
  2. 10.2 Asia Parkinson Disease Drug Market Size by Type
  3. 10.2.1 Asia Parkinson Disease Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Parkinson Disease Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Parkinson Disease Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Parkinson Disease Drug Market Size by Application
  7. 10.3.1 Asia Parkinson Disease Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Parkinson Disease Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Parkinson Disease Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Parkinson Disease Drug Market Size by Country
  11. 10.4.1 Asia Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Parkinson Disease Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Parkinson Disease Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Parkinson Disease Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Parkinson Disease Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Parkinson Disease Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Parkinson Disease Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Parkinson Disease Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Parkinson Disease Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Parkinson Disease Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Parkinson Disease Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Parkinson Disease Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst